<DOC>
	<DOCNO>NCT02075281</DOCNO>
	<brief_summary>The purpose study determine optimal dose regimen HM11260C , combination hypocaloric diet , reduce weight obese subject otherwise consider stable health .</brief_summary>
	<brief_title>Effect LAPS-Exendin Body Weight Obese Population</brief_title>
	<detailed_description>Phase 2 study</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<criteria>1 . Age : 18 year 65 year Genders : male female healthy obese population nondiabetes stable body weight least 3 month prior screen 2 . Exclusion Criteria Pregnant nursing ( lactate ) woman Druginduced obesity Diabetes mellitus ( type 1 , 2 , ) Previous surgical treatment obesity Any known history severe gastrointestinal ( GI ) disease intolerance Known history pancreatitis presence raise serum amylase lipase History suicide attempt recent history ( within 2 year prior screen ) major depression , anxiety , psychiatric disease require treatment prescription medication include selective serotonin reuptake inhibitor ( SSRIs ) , serotonin norepinephrine reuptake inhibitor ( SNRIs ) , antipsychotic , lithium .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>